Brucellosis Treatment Guidelines

Introduction to Brucellosis Treatment

• The optimal treatment for brucellosis is a six-week regimen of doxycycline (100 mg twice daily) combined with either streptomycin (1 g daily) for 2-3 weeks or rifampicin (600-900 mg daily) for six weeks, with the doxycycline-streptomycin combination showing superior efficacy 1

First-Line Treatment Options

• Doxycycline-Streptomycin combination is the preferred regimen with the lowest relapse rates, consisting of doxycycline 100 mg twice daily orally for 6 weeks and streptomycin 15 mg/kg daily intramuscularly for 2-3 weeks 1
• Doxycycline-Rifampicin is considered a second-choice regimen due to higher relapse rates, consisting of doxycycline 100 mg twice daily orally for 6 weeks and rifampicin 600-900 mg daily as a single morning dose for 6 weeks 1

Complicated Brucellosis

• Brucellar spondylitis (spinal involvement) may require aminoglycoside-containing regimens, which may be superior to rifampicin-containing ones, and treatment duration may need to be extended beyond the standard 6 weeks 2, 3
• Brucellar endocarditis is a high mortality complication requiring aggressive management with empirical antimicrobial selection and surgical intervention in most cases 3

Treatment Monitoring and Outcomes

• Relapse rates range from 5-15% even with appropriate treatment, and relapses are usually mild and can be treated with the same regimens 1
• Total treatment duration is typically 6 weeks for uncomplicated cases 1

Public Health Considerations

• In regions where brucellosis and tuberculosis coexist, consider the implications of using rifampicin, as this may contribute to mycobacterial resistance 1

Optimal Duration of Therapy for Brucellosis

Treatment Regimen and Duration

• The standard first-line regimens for uncomplicated brucellosis require 6 weeks of treatment, including Doxycycline-Streptomycin (DOX-STR) and Doxycycline-Rifampicin (DOX-RIF), with AI recommendation considered the gold standard with lowest relapse rates 4, 5
• Doxycycline-Gentamicin (DOX-GENT) is also a recommended regimen, with BI recommendation, consisting of doxycycline 100 mg twice daily orally for 6 weeks PLUS gentamicin 5 mg/kg daily parenterally for 7 days 4, 5

Clinical Context and Complications

• The American College of Physicians recommends careful attention to back pain in patients with brucellosis, as it may represent brucellar spondylitis, which requires extended treatment duration beyond 6 weeks 6
• The Infectious Diseases Society of America recommends extending treatment duration to 12 weeks (3 months) with aminoglycoside-containing regimens potentially superior to rifampicin-containing ones if MRI demonstrates spinal involvement 6

Important Caveats

• Shorter durations (3 weeks) of treatment are inadequate and associated with unacceptably high relapse rates, according to the Centers for Disease Control and Prevention 4, 5
• Longer durations (12 or 24 weeks) of treatment are reserved for complicated brucellosis, such as spondylitis, endocarditis, or neurobrucellosis, as recommended by the World Health Organization 6

Optimal Management of Brucellar Sacroiliac Joint Spondylitis

Treatment Duration

• In patients with brucellar spondylitis, extending antimicrobial therapy to 12 weeks (rather than a shorter course) is the key factor that improves clinical outcomes, as demonstrated by a meta‑analysis of multiple studies【7】.

Preferred Antimicrobial Regimen

• Aminoglycoside‑containing regimens (e.g., doxycycline plus streptomycin or gentamicin) are associated with better efficacy for brucellar spondylodiscitis compared with regimens that rely on rifampicin【7】.

Diagnostic Imaging

• Magnetic resonance imaging (MRI) of the spine should be performed in any patient with suspected spinal involvement (e.g., back pain), irrespective of the specific spinal segment, to identify sacroiliac or vertebral disease【7】.

Supportive Measures

• Spinal immobilization—particularly of the cervical region—should be instituted when spinal brucellosis is confirmed, to prevent serious neurological complications【7】.

Guideline Recommendations for Brucellar Sacroiliac Joint Spondylitis

Treatment Duration

• The Infectious Diseases Society of America (IDSA) 2015 guideline recommends a total of 12 weeks (3 months) of antimicrobial therapy for native vertebral osteomyelitis caused by Brucella species, including sacroiliac joint involvement. This recommendation carries a strong rating with moderate‑quality evidence【8】【9】.
• A 6‑week course, which is standard for uncomplicated brucellosis, is insufficient for osteoarticular complications such as sacroiliitis【8】【9】.

Preferred Antimicrobial Regimen

• Aminoglycoside‑containing regimens (e.g., doxycycline + streptomycin or doxycycline + gentamicin) are superior to rifampicin‑containing regimens for brucellar spondylodiscitis, yielding the lowest relapse rates【10】.
• The recommended regimen is:
  
  • Doxycycline 100 mg orally twice daily for 12 weeks plus either
    
    • Streptomycin 15 mg/kg intramuscularly daily for 2–3 weeks, or
    • Gentamicin 5 mg/kg parenterally daily for 7 days【10】.

Diagnostic Imaging

• Magnetic resonance imaging (MRI) confirmation of sacroiliac joint involvement is essential and supports the need for the extended 12‑week therapy【10】.
• Spinal MRI should be performed in any patient with back pain and confirmed brucellosis, regardless of the suspected level of involvement【10】.

Supportive Management

• Spinal immobilization is advised, especially when cervical involvement is present, to prevent severe neurological complications【10】.

Monitoring and Follow‑up

• Clinical improvement typically precedes radiographic resolution; therefore, persistent MRI abnormalities at 4–6 weeks should not trigger treatment changes if the patient’s symptoms and inflammatory markers (e.g., ESR, CRP) are improving【8】【9】.
• Do not discontinue therapy at 6 weeks even if clinical signs have improved, as early cessation leads to relapse in osteoarticular brucellosis【8】【9】.

Common Pitfalls to Avoid

• Avoid rifampicin‑based first‑line regimens for brucellar spondylitis because they are associated with inferior outcomes compared with aminoglycoside‑containing combinations【10】.
• Do not rely solely on imaging to assess treatment failure; combine clinical assessment with inflammatory marker trends for accurate evaluation【8】【9】.